Combination of antibody targeting and PTD-mediated intracellular toxin delivery for colorectal cancer therapy

Journal of Controlled Release

Volumn 194, Issue , 2014, Pages 197-210

  Shin, Meong Cheol ^a,b   Zhang, Jian ^c   Min, Kyoung Ah ^b   Lee, Kyuri ^b   Moon, Cheol ^d   Balthasar, Joseph P ^e   Yang, Victor C ^a,b  

^a TIANJIN MEDICAL UNIVERSITY   (China)

^b UNIVERSITY OF MICHIGAN   (United States)

^c SOOCHOW UNIVERSITY   (China)

^d Sunchon National University   (South Korea)

^e UNIVERSITY AT BUFFALO   (United States)

Author keywords

Anti CEA monoclonal antibody; Cancer; Gelonin; Heparin; Protein transduction domain

Indexed keywords

BACTERIOPHAGES; CELLS; CHEMOTHERAPY; CYTOLOGY; DRUG DOSAGE; MONOCLONAL ANTIBODIES; POLYSACCHARIDES; TOXICITY; TUMORS;

CANCER; CARCINOEMBRYONIC ANTIGEN; CELL-PENETRATING PEPTIDE; GELONIN; HEPARIN; INHIBITION OF TUMOR GROWTH; MONOCLONAL ANTIBODIES (MAB); PROTEIN TRANSDUCTION DOMAINS;

DISEASES;

CARCINOEMBRYONIC ANTIGEN; CELL PENETRATING PEPTIDE; GELONIN; HEPARIN; HYBRID PROTEIN; PROTEIN TRANSDUCTION DOMAIN; UNCLASSIFIED DRUG; ANTINEOPLASTIC AGENT; GEL PROTEIN, GELONIUM MULTIFLORUM; MONOCLONAL ANTIBODY; PRIMER DNA; PROTEIN BINDING; RIBOSOME INACTIVATING PROTEIN 1; TRANSACTIVATOR PROTEIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; ARTICLE; COLORECTAL CANCER; CONTROLLED STUDY; DRUG DELIVERY SYSTEM; DRUG EFFICACY; FEASIBILITY STUDY; GENETIC ENGINEERING; HCT116 CELL LINE; HUMAN; HUMAN CELL; IC50; IN VITRO STUDY; IN VIVO STUDY; MALE; MOUSE; NONHUMAN; STATIC ELECTRICITY; TUMOR GROWTH; TUMOR XENOGRAFT; ANIMAL; CHEMISTRY; COLORECTAL NEOPLASMS; DRUG SCREENING; GENE VECTOR; MAXIMUM TOLERATED DOSE; METABOLISM; NUDE MOUSE; TISSUE DISTRIBUTION;

ANIMALS; ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC AGENTS, PHYTOGENIC; CARCINOEMBRYONIC ANTIGEN; CELL-PENETRATING PEPTIDES; COLORECTAL NEOPLASMS; DNA PRIMERS; DRUG DELIVERY SYSTEMS; GENE PRODUCTS, TAT; GENETIC VECTORS; HEPARIN; HUMANS; MALE; MAXIMUM TOLERATED DOSE; MICE; MICE, NUDE; PROTEIN BINDING; RIBOSOME INACTIVATING PROTEINS, TYPE 1; TISSUE DISTRIBUTION; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84907200459     PISSN: 01683659     EISSN: 18734995     Source Type: Journal    
DOI: 10.1016/j.jconrel.2014.08.030     Document Type: Article

References (49)

1. R. Siegel, J. Ma, Z. Zou, and A. Jemal Cancer statistics, 2014 CA Cancer J. Clin. 64 2014 9 29
2. S. Giacchetti, M. Itzhaki, G. Gruia, R. Adam, R. Zidani, F. Kunstlinger, S. Brienza, E. Alafaci, F. Bertheault-Cvitkovic, C. Jasmin, M. Reynes, H. Bismuth, J.L. Misset, and F. Levi Long-term survival of patients with unresectable colorectal cancer liver metastases following infusional chemotherapy with 5-fluorouracil, leucovorin, oxaliplatin and surgery Ann. Oncol. 10 1999 663 669
3. A. Schroeder, D.A. Heller, M.M. Winslow, J.E. Dahlman, G.W. Pratt, R. Langer, T. Jacks, and D.G. Anderson Treating metastatic cancer with nanotechnology Nat. Rev. Cancer 12 2012 39 50
4. D.B. Longley, D.P. Harkin, and P.G. Johnston 5-Fluorouracil: mechanisms of action and clinical strategies Nat. Rev. Cancer 3 2003 330 338
5. A. Grothey, D. Sargent, R.M. Goldberg, and H.J. Schmoll Survival of patients with advanced colorectal cancer improves with the availability of fluorouracil-leucovorin, irinotecan, and oxaliplatin in the course of treatment J. Clin. Oncol. 22 2004 1209 1214
6. H. Kelly, and R.M. Goldberg Systemic therapy for metastatic colorectal cancer: current options, current evidence J. Clin. Oncol. 23 2005 4553 4560
7. M. Puri, I. Kaur, M.A. Perugini, and R.C. Gupta Ribosome-inactivating proteins: current status and biomedical applications Drug Discov. Today 17 2012 774 783
8. B.L. Davidson, and P.B. McCray Jr. Current prospects for RNA interference-based therapies Nat. Rev. Genet. 12 2011 329 340
9. M.A. Kay State-of-the-art gene-based therapies: the road ahead Nat. Rev. Genet. 12 2011 316 328
10. F. Stirpe, S. Olsnes, and A. Pihl Gelonin, a new inhibitor of protein synthesis, nontoxic to intact cells. Isolation, characterization, and preparation of cytotoxic complexes with concanavalin A J. Biol. Chem. 255 1980 6947 6953
11. S.F. Atkinson, T. Bettinger, L.W. Seymour, J.P. Behr, and C.M. Ward Conjugation of folate via gelonin carbohydrate residues retains ribosomal-inactivating properties of the toxin and permits targeting to folate receptor positive cells J. Biol. Chem. 276 2001 27930 27935
12. M.C. Shin, J. Zhang, A.E. David, W.E. Trommer, Y.M. Kwon, K.A. Min, J.H. Kim, and V.C. Yang Chemically and biologically synthesized CPP-modified gelonin for enhanced anti-tumor activity J. Control. Release 172 2013 169 178
13. M.C. Shin, J. Zhang, K.A. Min, K. Lee, Y. Byun, A.E. David, H. He, and V.C. Yang Cell-penetrating peptides: achievements and challenges in application for cancer treatment J. Biomed. Mater. Res. 102 2014 575 587
14. H. Brooks, B. Lebleu, and E. Vives Tat peptide-mediated cellular delivery: back to basics Adv. Drug Deliv. Rev. 57 2005 559 577
15. J.S. Wadia, and S.F. Dowdy Transmembrane delivery of protein and peptide drugs by TAT-mediated transduction in the treatment of cancer Adv. Drug Deliv. Rev. 57 2005 579 596
16. Y. Huang, Y. Jiang, H. Wang, J. Wang, M.C. Shin, Y. Byun, H. He, Y. Liang, and V.C. Yang Curb challenges of the "Trojan Horse" approach: smart strategies in achieving effective yet safe cell-penetrating peptide-based drug delivery Adv. Drug Deliv. Rev. 65 2013 1299 1315
17. A.M. Wu, and P.D. Senter Arming antibodies: prospects and challenges for immunoconjugates Nat. Biotechnol. 23 2005 1137 1146
18. G.P. Adams, and L.M. Weiner Monoclonal antibody therapy of cancer Nat. Biotechnol. 23 2005 1147 1157
19. P. Gold, and S.O. Freedman Specific carcinoembryonic antigens of the human digestive system J. Exp. Med. 122 1965 467 481
20. S. Hammarstrom The carcinoembryonic antigen (CEA) family: structures, suggested functions and expression in normal and malignant tissues Semin. Cancer Biol. 9 1999 67 81
21. T. Meyer, A.M. Gaya, G. Dancey, M.R. Stratford, S. Othman, S.K. Sharma, D. Wellsted, N.J. Taylor, J.J. Stirling, L. Poupard, L.K. Folkes, P.S. Chan, R.B. Pedley, K.A. Chester, K. Owen, J.A. Violet, A. Malaroda, A.J. Green, J. Buscombe, A.R. Padhani, G.J. Rustin, and R.H. Begent A phase I trial of radioimmunotherapy with 131I-A5B7 anti-CEA antibody in combination with combretastatin-A4-phosphate in advanced gastrointestinal carcinomas Clin. Cancer Res. 15 2009 4484 4492
22. S. Shibata, A. Raubitschek, L. Leong, M. Koczywas, L. Williams, J. Zhan, and J.Y. Wong A phase I study of a combination of yttrium-90-labeled anti-carcinoembryonic antigen (CEA) antibody and gemcitabine in patients with CEA-producing advanced malignancies Clin. Cancer Res. 15 2009 2935 2941
23. S.R. Urva, and J.P. Balthasar Target mediated disposition of T84.66, a monoclonal anti-CEA antibody: application in the detection of colorectal cancer xenografts MAbs 2 2010 67 72
24. M. Hossann, Z. Li, Y. Shi, U. Kreilinger, J. Buttner, P.D. Vogel, J. Yuan, J.G. Wise, and W.E. Trommer Novel immunotoxin: a fusion protein consisting of gelonin and an acetylcholine receptor fragment as a potential immunotherapeutic agent for the treatment of myasthenia gravis Protein Expr. Purif. 46 2006 73 84
25. S.R. Urva, V.C. Yang, and J.P. Balthasar An ELISA for quantification of T84.66, a monoclonal anti-CEA antibody, in mouse plasma J. Immunoass. Immunochem. 31 2010 1 9
26. G.L. Ellman Tissue sulfhydryl groups Arch. Biochem. Biophys. 82 1959 70 77
27. L.B. Jaques, and A. Wollin A modified method for the colorimetric determination of heparin Can. J. Physiol. Pharmacol. 45 1967 787 794
28. A.J. Cole, A.E. David, J. Wang, C.J. Galban, H.L. Hill, and V.C. Yang Polyethylene glycol modified, cross-linked starch-coated iron oxide nanoparticles for enhanced magnetic tumor targeting Biomaterials 32 2011 2183 2193
29. N. Billinton, and A.W. Knight Seeing the wood through the trees: a review of techniques for distinguishing green fluorescent protein from endogenous autofluorescence Anal. Biochem. 291 2001 175 197
30. S. Madan, and P.C. Ghosh Interaction of gelonin with macrophages: effect of lysosomotropic amines Exp. Cell Res. 198 1992 52 58
31. X. Zhou, J. Qiu, Z. Wang, N. Huang, X. Li, Q. Li, Y. Zhang, C. Zhao, C. Luo, N. Zhang, X. Teng, Z. Chen, X. Liu, X. Yu, W. Wu, Y.Q. Wei, and J. Li In vitro and in vivo anti-tumor activities of anti-EGFR single-chain variable fragment fused with recombinant gelonin toxin J. Cancer Res. Clin. Oncol. 138 2012 1081 1090
32. Y. Cao, J.W. Marks, Z. Liu, L.H. Cheung, W.N. Hittelman, and M.G. Rosenblum Design optimization and characterization of Her2/neu-targeted immunotoxins: comparative in vitro and in vivo efficacy studies Oncogene 33 2014 429 439
33. H. Zhou, W.N. Hittelman, H. Yagita, L.H. Cheung, S.S. Martin, J.A. Winkles, and M.G. Rosenblum Antitumor activity of a humanized, bivalent immunotoxin targeting fn14-positive solid tumors Cancer Res. 73 2013 4439 4450
34. F. Stirpe, and M.G. Battelli Ribosome-inactivating proteins: progress and problems Cell. Mol. Life Sci. 63 2006 1850 1866
35. G.R. Devi siRNA-based approaches in cancer therapy Cancer Gene Ther. 13 2006 819 829
36. S. El-Andaloussi, P. Jarver, H.J. Johansson, and U. Langel Cargo-dependent cytotoxicity and delivery efficacy of cell-penetrating peptides: a comparative study Biochem. J. 407 2007 285 292
37. E. Vives, J. Schmidt, and A. Pelegrin Cell-penetrating and cell-targeting peptides in drug delivery Biochim. Biophys. Acta 1786 2008 126 138
38. S.R. Schwarze, A. Ho, A. Vocero-Akbani, and S.F. Dowdy In vivo protein transduction: delivery of a biologically active protein into the mouse Science 285 1999 1569 1572
39. F. Stirpe, L. Barbieri, M.G. Battelli, M. Soria, and D.A. Lappi Ribosome-inactivating proteins from plants: present status and future prospects Nat. Biotechnol. 10 1992 405 412
40. G. Agnelli, F. Piovella, P. Buoncristiani, P. Severi, M. Pini, A. D'Angelo, C. Beltrametti, M. Damiani, G.C. Andrioli, R. Pugliese, A. Iorio, and G. Brambilla Enoxaparin plus compression stockings compared with compression stockings alone in the prevention of venous thromboembolism after elective neurosurgery N. Engl. J. Med. 339 1998 80 85
41. S. Absar, S. Choi, V.C. Yang, and Y.M. Kwon Heparin-triggered release of camouflaged tissue plasminogen activator for targeted thrombolysis J. Control. Release 157 2012 46 54
42. B. Chertok, A.E. David, and V.C. Yang Magnetically-enabled and MR-monitored selective brain tumor protein delivery in rats via magnetic nanocarriers Biomaterials 32 2011 6245 6253
43. L.C. Chang, H.F. Lee, Z. Yang, and V.C. Yang Low molecular weight protamine (LMWP) as nontoxic heparin/low molecular weight heparin antidote (I): preparation and characterization AAPS PharmSci 3 2001 E17
44. M. Neumaier, L. Shively, F.S. Chen, F.J. Gaida, C. Ilgen, R.J. Paxton, J.E. Shively, and A.D. Riggs Cloning of the genes for T84.66, an antibody that has a high specificity and affinity for carcinoembryonic antigen, and expression of chimeric human/mouse T84.66 genes in myeloma and Chinese hamster ovary cells Cancer Res. 50 1990 2128 2134
45. V. Boudousq, L. Bobyk, M. Busson, V. Garambois, M. Jarlier, P. Charalambatou, A. Pelegrin, S. Paillas, N. Chouin, F. Quenet, P. Maquaire, J. Torgue, I. Navarro-Teulon, and J.P. Pouget Comparison between internalizing anti-HER2 mAbs and non-internalizing anti-CEA mAbs in alpha-radioimmunotherapy of small volume peritoneal carcinomatosis using 212Pb PLoS ONE 8 2013 e69613
46. J.N. Bryan, F. Jia, H. Mohsin, G. Sivaguru, W.H. Miller, C.J. Anderson, C.J. Henry, and M.R. Lewis Comparative uptakes and biodistributions of internalizing vs. noninternalizing copper-64 radioimmunoconjugates in cell and animal models of colon cancer Nucl. Med. Biol. 32 2005 851 858
47. H. He, J. Sheng, A.E. David, Y.M. Kwon, J. Zhang, Y. Huang, J. Wang, and V.C. Yang The use of low molecular weight protamine chemical chimera to enhance monomeric insulin intestinal absorption Biomaterials 34 2013 7733 7743
48. T. Jiang, E.S. Olson, Q.T. Nguyen, M. Roy, P.A. Jennings, and R.Y. Tsien Tumor imaging by means of proteolytic activation of cell-penetrating peptides Proc. Natl. Acad. Sci. U. S. A. 101 2004 17867 17872
49. M.G. Battelli Cytotoxicity and toxicity to animals and humans of ribosome-inactivating proteins Mini Rev. Med. Chem. 4 2004 513 521